Thursday, June 25, 2009

A review of the CSC paradigm

Controversial Cancer Stem Cells Offer New Direction For Treatment, ScienceDaily, June 25, 2009. [FriendFeed entry]. First paragraph:
In a review in Science, a University of Rochester Medical Center researcher sorts out the controversy and promise around a dangerous subtype of cancer cells, known as cancer stem cells, which seem capable of resisting many modern treatments.
Based on this review: The Increasing Complexity of the Cancer Stem Cell Paradigm by Jeffrey M Rosen and Craig T Jordan, Science 2009(Jun 26); 324(5935): 1670-3. First paragraph:
The investigation and study of cancer stem cells (CSCs) have received enormous attention over the past 5 to 10 years but remain topics of considerable controversy. Opinions about the validity of the CSC hypothesis, the biological properties of CSCs, and the relevance of CSCs to cancer therapy differ widely. In the following commentary, we discuss the nature of the debate, the parameters by which CSCs can or cannot be defined, and the identification of new potential therapeutic targets elucidated by considering cancer as a problem in stem cell biology.

Chief Scientific Officer leaving CIRM

Chief Scientific Officer Leaving California Institute of Regenerative Medicine by Monya Baker, The Niche, June 25, 2009. Excerpt:
Marie Csete will resign her post from the California Institute of Regenerative Medicine as of Aug 1st, according to the California Stem Cell Report, Consumer Watchdog and the Silicon Valley Business Journal. The resignation comes just before a huge round of grants aiming to push stem cells toward clinical trials is due to be awarded.
From the Silicon Valley Business Journal: State stem cell agency’s science officer to resign by Ron Leuty, June 24, 2009. Excerpt:
Csete has been an important part of CIRM’s effort to not only review and award grants but, highlighted most recently, to monitor grants after awards have been made. CIRM terminated three research grants this month due to lack of progress.
From the California Stem cell Report: Csete Quits CIRM on Eve of Huge Grant Round by David Jensen, June 24, 2009. Excerpt:
Csete's departure comes as the agency is about to embark on its most ambitious and largest round of research grants – a complex, $210 million “disease team” effort aimed at pushing research towards clinical trials.

Wednesday, June 24, 2009

Hypoxic responses in glioma stem cells

Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells by Zhizhong Li and 11 co-authors, including Jeremy N Rich, Cancer Cell 2009(Jun 2); 15(6): 501-13 [FriendFeed entry] PubMed Abstract:
Glioblastomas are lethal cancers characterized by florid angiogenesis promoted in part by glioma stem cells (GSCs). Because hypoxia regulates angiogenesis, we examined hypoxic responses in GSCs. We now demonstrate that hypoxia-inducible factor HIF2alpha and multiple HIF-regulated genes are preferentially expressed in GSCs in comparison to non-stem tumor cells and normal neural progenitors. In tumor specimens, HIF2alpha colocalizes with cancer stem cell markers. Targeting HIFs in GSCs inhibits self-renewal, proliferation, and survival in vitro, and attenuates tumor initiation potential of GSCs in vivo. Analysis of a molecular database reveals that HIF2A expression correlates with poor glioma patient survival. Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies.

Monday, June 22, 2009

About CD133 as a marker for CSC

CD133 as a marker for cancer stem cells: progresses and concerns by Yaojiong Wu, Philip Yuguang Wu, Stem Cells Dev 2009(May 2) [Epub ahead of print][ResearchGATE entry][FriendFeed entry] PubMed Abstract:
Increasing evidence supports the cancer stem cell hypothesis, which postulates that cancer stem cells are responsible for tumor initiation, metastasis and resistance to treatments. Therefore, they are the cells to target to cure a cancer. To study the behavior of cancer stem cells, markers for prospective isolation of cancer stem cells are crucial. Recently, CD133 has been used extensively as a marker for the identification of stem cells from normal and cancerous tissues. Several more recent studies, however, indicate that CD133 are expressed in differentiated epithelial cells in various organs, and CD133-negative cancer cells can also initiate tumors. The findings suggest that CD133 is not restricted to somatic stem cells and cancer stem cells. However, in many cases CD133 may be used in combination with other markers or methods to acquire stem cells. In this review, we summarize findings in CD133 expression in various tissues and critically discuss its applications in stem cell isolation.

Saturday, June 20, 2009

CSC and radiotherapy

Cancer stem cells and radiotherapy by Michael Baumann and 4 co-authors, Int J Radiat Biol 2009(May); 85(5): 391-402 [PubMed Citation][Full text is publicly accessible (via Gratis OA)][Found via ResearchGATE, see: publication link].

In this review, the authors question the interpretation of data in a much-cited article by Shideng Bao and 8 co-authors, including Jeremy N Rich, entitled: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature 2006(Dec 7); 444(7120): 756-60 [Epub 2006 Oct 18][PubMed Citation][Full text PDF is publicly accessible (via Gratis OA)][Another publicly accessible version].

Excerpt from the review by Baumann et al. 2009:
However, interpretation of these data [of Boa et al] is limited by several factors including the fact that enrichment of CD133+ cells after irradiation may possibly reflect differences in proliferative capability rather than differences in radiosensitivity, and that the irradiation dose of 2 Gy might not be sufficient to generate detectable differences in the transplantation assay used (Baumann et al. 2008).
[PubMed Citation for the reference to Baumann et al. 2008].

Another excerpt from Baumann et al. 2009:
In summary, a higher radioresistance of cancer stem cells compared to non-stem cells has not been proven. More experiments, comparing the results of surface-marker based quantitative transplantation assays with and without irradiation after different doses in different tumours, are necessary before firm conclusions on the radioresistance of cancer stem cells can be drawn.
Comment: The intrinsic radiosensitivity of cancer stem cells compared to non-stem cells is, from the perspective of radiation oncology, an important issue that has been investigated for many years. Some of this history is reviewed by Baumann et al. 2009. The issue needs to be resolved.

Wednesday, June 17, 2009

Malignant Pleural Effusions (MPE) as a model

Researchers Develop Model that May Help Identify Lung Cancer Stem Cells, News Release, UCLA Jonsson Comprehensive Cancer Center, June 16, 2009. First paragraph:
Researchers at UCLA’s Jonsson Comprehensive Cancer Center, on a quest to find lung cancer stem cells, have developed a unique model to allow further investigation into the cells that many believe may be at the root of all lung cancers.
See also: Researchers Use Malignant Pleural Effusion as Model for Lung Cancer, Genetic Engineering & Biotechnology News, June 16, 2009.

Based on: The Malignant Pleural Effusion as a Model to Investigate Intratumoral Heterogeneity in Lung Cancer by Saroj K Basak and 7 co-authors, including Raj K Batra, PLoS ONE 2009(Jun 12); 4(6): e5884 [Entry in FriendFeed]. Abstract:
Malignant Pleural Effusions (MPE) may be useful as a model to study hierarchical progression of cancer and/or intratumoral heterogeneity. To strengthen the rationale for developing the MPE-model for these purposes, we set out to find evidence for the presence of cancer stem cells (CSC) in MPE and demonstrate an ability to sustain intratumoral heterogeneity in MPE-primary cultures. Our studies show that candidate lung CSC-expression signatures (PTEN, OCT4, hTERT, Bmi1, EZH2 and SUZ12) are evident in cell pellets isolated from MPE, and MPE-cytopathology also labels candidate-CSC (CD44, cMET, MDR-1, ALDH) subpopulations. Moreover, in primary cultures that use MPE as the source of both tumor cells and the tumor microenvironment (TME), candidate CSC are maintained over time. This allows us to live-sort candidate CSC-fractions from the MPE-tumor mix on the basis of surface markers (CD44, c-MET, uPAR, MDR-1) or differences in xenobiotic metabolism (ALDH). Thus, MPE-primary cultures provide an avenue to extract candidate CSC populations from individual (isogenic) MPE-tumors. This will allow us to test whether these cells can be discriminated in functional bioassays. Tumor heterogeneity in MPE-primary cultures is evidenced by variable immunolabeling, differences in colony-morphology, and differences in proliferation rates of cell subpopulations. Collectively, these data justify the ongoing development of the MPE-model for the investigation of intratumoral heterogeneity, tumor-TME interactions, and phenotypic validation of candidate lung CSC, in addition to providing direction for the pre-clinical development of rational therapeutics.

Tuesday, June 16, 2009

Presentation on miRNA replacement therapy

Mirna Therapeutics Presents Data at Keystone Symposium on MicroRNA and Cancer, Business Wire, June 15, 2009 [Entry in FriendFeed]. Excerpt:
The expression of miR-34 is reduced in a variety of cancers as well as in cancer stem cells, suggesting that miR-Rx34 may have broad applicability as an anti-cancer agent in miRNA replacement strategies.